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Background: The best way to treat in-stent restenosis (ISR) after drug-eluting stent (DES) implan-
tation remains unclear. The aim of this study was to evaluate angiographic restenosis and target
lesion revascularization (TLR) at 8 months after intervention in patients with DES-ISR, and to
identify predictive factors of subsequent TLR after treatment of DES-ISR.
Methods and results: A total of 100 patients with 105 lesions underwent subsequent interven-
tion for DES-ISR between April 2004 and January 2009. At baseline, focal and diffuse ISR were
observed in 76.2% and 23.8%. DES-ISR was treated by ﬁve modalities: sirolimus-eluting stent
(n = 42); paclitaxel-eluting stent (n = 24); balloon angioplasty (n = 23); cutting balloon angio-
plasty (n = 14); and bare-metal stent (n = 2). Angiographic follow-up data were available for 95
lesions (91%). The rates of angiographic restenosis and TLR were 37.9% and 33.3%. Late loss of
sirolimus-eluting stent, paclitaxel-eluting stent, cutting balloon, and balloon angioplasty were
0.50mm, 0.49mm, 0.93mm, and 1.10mm. By multivariate analysis, totally occluded ISR (OR
15.43, p = 0.0005), diabetes mellitus (OR 3.45, p = 0.02), and re-stenting with DES (OR 0.14,
p = 0.0002) were identiﬁed as independent predictors of TLR.
Conclusions: The restenosis rate was signiﬁcant in this cohort of patients with DES-ISR. Angio-
graphic pattern of DES-ISR and diabetes mellitus are the most important predictors of TLR,
whereas re-stenting with DES is protective.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
∗ Corresponding author. Tel.: +81 3 3468 1251; fax: +81 3 3468 1269.
E-mail address: raisuke@live.jp (R. Iijima).








































































































n-stent restenosis (ISR), which is almost always attributable
o intimal hyperplasia, was a signiﬁcant clinical problem
n the era of bare-metal stents (BMS) [1]. Several percuta-
eous coronary intervention (PCI) techniques using balloon
ngioplasty and atherectomy devices failed to improve the
ong-term outcomes after treatment of ISR [2—4]. Subse-
uently, an additional stent implantation with drug-eluting
tent (DES) has emerged as the most promising way to treat
MS-ISR [5,6]. The advent of DES remarkably reduced intimal
yperplasia after stent implantation and has demonstrated
n the pivotal trials that the rate of restenosis approximated
o single digits in selected patients. Still, DES has not elim-
nated restenosis completely [7]. As expected, the rates of
ngiographic restenosis and target lesion revascularization
TLR) are increasing when the use of DES widened among
atients with off-label indications and those with more com-
lex lesions [8,9]. Therefore, even in the era of DES, ISR
as become an important clinical issue. Previous studies
ave reported two approaches, a balloon angioplasty or a
e-stenting with second DES, to treat for DES-ISR, but the
ptimal management for DES-ISR is still not clearly deﬁned
10,11]. Identifying predictive factors for repeat DES-ISR
ay help improve outcomes after PCI in the DES era. The aim
f this study was to evaluate angiographic restenosis and TLR
t 8 months after PCI in patients with DES-ISR, and to iden-




his analysis comprised a total of 100 patients with 105
esions undergoing intervention for DES-ISR from April 2004
o January 2009 from 3 hospitals. All lesions were previously
mplanted on de-novo lesions by either a sirolimus-eluting
tent (Cypher; Cordis, Johnson & Johnson, Miami Lakes,
L, USA) or paclitaxel-eluting stents (Taxus; Boston Scien-
iﬁc, Boston, MA, USA). The eligible patients were: (1) ﬁrst
SR, which was deﬁned as luminal re-narrowing greater than
0% within the stented segment or within a 5mm segment
ither proximal or distal to the stent edges; (2) objective
vidence of ischemic signs, either symptoms or changes in
T-T segment on the resting electrocardiogram, or inducible
schemia with exercise stress test. Written informed consent
as given by all patients participating in the study.
CI and procedural management
bolus of 100 IU/kg of heparin was administered after inser-
ion of the sheath and titrated to maintain an activated
lotting time >250 s throughout the procedure. The device
o treat ISR was selected at operator discretion. The sub-
equent PCI was performed either with balloon angioplasty
ncluding cutting balloon angioplasty or with re-stenting by
he same or a different DES. Target lesions were predi-
atated with conventional angioplasty balloons. After stent
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o achieve a satisfactory angiographic result of less than 25%
esidual stenosis by visual estimate. All patients received
spirin 100mg plus ticlopidine 200mg or clopidgrel 75mg
er day for at least 12 months and other cardiac medications
rescribed by the physicians.
ollow-up and deﬁnitions
ngiographic follow-up was scheduled at 8 months after PCI
or DES-ISR. TLR was deﬁned as revascularization involving
he target lesion. Based on the classiﬁcation reported by
ehran et al., ISR was classiﬁed on the basis of length of
he restenotic lesion in relation to the stent length, namely 3
ypes of ISR have been deﬁned: (1) focal ISR ≤10mm length;
2) diffuse ISR >10mm, within the stent borders; (3) totally
ccluded ISR [12]. Stent fracture was deﬁned as complete
eparation of the stent by angiographic estimate. Follow-
p was achieved in all patients. Patients who had cardiac
omplaints underwent a complete clinical, electrocardio-
raphic, and laboratory evaluation.
uantitative coronary angiography
uantitative coronary angiography was performed before,
mmediately, and 8 months after the procedure accord-
ng to edge detection algorithms. Minimal lumen diameter
MLD), reference vessel diameter, diameter of stenosis (DS),
nd lesion length were measured using a single matched
orst view. Late luminal loss was deﬁned as the differ-
nce between the MLD immediately after the procedure
nd the MLD at 8 months after PCI. The 2nd ISR (subse-
uently restenosis after treatment of DES-ISR) was deﬁned
s greater than 50% DS by quantitative coronary angiography
n follow-up angiography.
tatistical analysis
he data are presented as mean± SD or counts (%). Dif-
erences between groups were assessed using ANOVA test
or continuous variables. For the main analysis to identity
ndependent predictors of TLR, we used a 2-step analy-
is. (1) Univariate analysis was used to select the clinical,
ngiographic, or procedural factors of TLR. Continuous vari-
bles were transformed to binary data with 1 for the
resence of assumed risk factor and 0 otherwise. For exam-
le, age was dichotomized to elderly or not (≥65 years
ersus <65 years), ejection fraction dichotomized to low
r normal (<40% versus ≥40%), and treatment for DES-ISR
lso dichotomized to the 2 strategies (re-stenting with DES
both sirolimus- and paclitaxel-eluting stents] versus bal-
oon angioplasty [included cutting balloon angioplasty]). We
lso used the median of each factor as the cut-off point
or this division, avoiding arbitrary divisions. (2) Univariate
redictors with p < 0.05 were entered into a stepwise mul-
ivariate logistic regression model. The odds ratio (OR) and
5% conﬁdence intervals (CI) were calculated for the ﬁnal
ultivariate model. Statistical signiﬁcance was accepted for
ll p-values < 0.05.
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Table 1 Baseline characteristics of patients.
n = 100 (%)
Age, years 66± 11
Women, n 16 (16)
Arterial hypertension, n 42 (42)
Diabetes mellitus, n 57 (57)
Hypercholesterolemia, n 52 (52)
Current smoking, n 65 (65)
Hemodialysis, n 23 (23)
Left ventricular ejection fraction, % 59± 15
Clinical presentation
Stable angina, n 95 (95)
Acute coronary syndrome, n 5 (5)
Table 2 Baseline angiographic characteristics in in-stent
restenosis lesions.
n = 105 (%)
Treated coronary artery, n
Left anterior descending 45 (42.9)
Right 35 (33.3)
Left circumﬂex 21 (20)
Left main tract 4 (3.8)
Morphologic pattern, n
Focal (lesion length ≤10mm) 80 (76.2)
Diffuse (lesion length >10mm) 25 (23.8)
Total occlusion 13 (12.4)
Before intervention
Reference vessel diameter, mm 2.78± 0.85
Minimum lumen diameter, mm 0.89± 0.79
%Diameter stenosis, % 69.4± 24.6
Lesion length, mm 9.8± 10.4
Type of drug-eluting stent, n
Sirolimus-eluting stent 88 (83.8)
Paclitaxel-eluting stent 17 (16.2)
Stent length, mm 43± 27
Stent diameter, mm 3.1± 0.3
Maximal pressure, atm 18± 3
Prior bifurcation stenting with 2
drug-eluting stent, n
28 (26.7)
Stent fracture, n 7 (6.7)
Data are presented as number of patients and lesions (%) or
mean± SD.
Table 3 Procedural characteristics.
n = 105 (%)
Type of intervention, n
Sirolimus-eluting stent 42 (40.0)
Paclitaxel-eluting stent 24 (22.9)
Balloon angioplasty 23 (21.9)
Cutting balloon angioplasty 14 (13.3)
Bare-metal stent 2 (1.9)
Post intervention
Minimum lumen diameter, mm 2.28± 0.87
Diameter stenosis, % 22.4± 15.8Data are presented as number of patients and lesions (%) or
mean± SD.
Results
The baseline clinical and angiographic characteristics are
shown in Tables 1 and 2. The mean age was 66 years, 16% of
patients were women, 57% had diabetes, and 23% of patients
were on hemodialysis. The most frequent clinical presen-
tation pattern was stable angina when undergoing PCI for
DES-ISR. A diffuse ISR was observed in 25 lesions (23.8%)
and occlusive ISR pattern in 13 lesions. On the other hand,
focal ISR pattern was seen in 80 lesions (76.2%). At the
time of initial stent implantation, bifurcation stenting with
2 DES was placed in 28 lesions and the mean stent length
was 43mm. ISR after sirolimus- and paclitaxel-eluting stents
was seen in 88 (83.8%) and 17 (16.2%) lesions, respectively.
DES-ISR was treated by ﬁve modalities, including sirolimus-
eluting stent, paclitaxel-eluting stent, balloon angioplasty,
cutting balloon angioplasty, and BMS (Table 3). When
looked at by type of DES-ISR, ISR after sirolimus-eluting
stent was treated by the following devices: sirolimus-
eluting stent implantation (43.2%); paclitaxel-eluting stent
implantation (14.8%); balloon angioplasty (25%); cutting
balloon angioplasty (14.8%); and BMS implantation (2.2%).
Whereas treatment of ISR after paclitaxel-eluting stent
was used, included paclitaxel-eluting stent implantation
(64.7%), sirolimus-eluting stent implantation (23.5%), bal-
loon angioplasty (5.9%), and cutting balloon angioplasty
(5.9%). Stent fracture was seen in 6.7% of them. Proce-
dural success was 100%. Angiographic follow-up data were
available for 95 (91%) lesions. The rate of angiographic
restenosis was 37.9%. In-stent late luminal loss of sirolimus-
Data are presented as number of patients and lesions (%) or
mean± SD.
Table 4 Multivariate analysis of risk for subsequent target lesion revascularization.
Variable Univariate Multivariate
p-Value Odds ratio 95% CI p-Value
Totally occluded ISR pattern 0.007 15.43 3.29—72.45 0.0005
Diabetes mellitus 0.01 3.45 1.20—9.93 0.02
Re-stenting with drug-eluting stent 0.0002 0.14 0.05—0.39 0.0002
Prior bifurcation stenting with 2 DES 0.03
ISR, in-stent restenosis; DES, drug-eluting stent.
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Figure 1 Late luminal loss in sirolimus-eluting stent (SES),
paclitaxel-eluting stent (PES), cutting balloon angioplasty
(CBA), and balloon angioplasty (BA) groups. Signiﬁcantly








































Figure 2 Angiographic restenosis and TLR in 3 subsets.
(Upper) Morphologic ISR pattern, *p: focal versus totally

























haclitaxel-eluting stent groups compared to balloon angioplasty
roup (0.50± 0.99mm, 0.49± 1.00mm, and 1.10± 0.68mm,
< 0.05).
luting stent, paclitaxel-eluting stent, cutting balloon, and
alloon angioplasty were 0.50± 0.99mm, 0.49± 1.00mm,
.93± 0.94mm, and 1.10± 0.68mm (Fig. 1). Re-stenting
ith DES (both sirolimus- and paclitaxel-eluting stents) was
lower late lumen loss than balloon angioplasty includ-
ng cutting balloon: (0.51± 0.99mm versus 1.02± 0.78mm,
= 0.02). During the follow-up, TLR occurred in 35 patients
33.3%). Results of multivariate analysis are shown in
able 4. The following potential factors were entered into
he model: age, female sex, diabetes, arterial hypertension,
urrent smoking, hypercholesterolemia, hemodialysis, ejec-
ion fraction <40%, clinical presentation, prior bifurcation
tenting with 2 DES, stent length, stent diameter, incidence
f stent fracture, ISR after sirolimus-eluting stent, focal ISR
attern, diffuse ISR pattern, totally occluded ISR pattern,
re-vessel diameter, pre-MLD, pre % DS, lesion length, post-
LD, post % DS, maximum pressure, re-stenting with DES.
he multivariate analysis revealed that totally occluded ISR
OR 15.43; 95% CI 3.29—72.45, p = 0.0005), and the presence
f diabetes mellitus (OR 3.45; 95% CI 1.20—9.93, p = 0.02)
ere independent predictors of TLR. On the other hand, re-
tenting with DES for DES-ISR was a protective factor (OR
.14; 95% CI 0.05—0.39, p = 0.0002). Fig. 2 shows the rates
f angiographic restenosis and TLR in 3 subsets according to
he multivariate analysis.
iscussion
n the present study, we analyzed the predictors of subse-
uent TLR in a series of consecutive patients with DES-ISR
ndergoing PCI. Overall rates of angiographic and clinical
estenosis were 37.9% and 33.3%, respectively, further sug-
esting that DES-ISR remains an unsolved problem. Our main
esults can be summarized as follows: in the era of DES, mor-
hologic pattern of ISR plays a role for predicting recurrence
f restenosis, and in particular, totally occluded ISR is asso-
iated with an increased risk. Furthermore, the presence





pith DES versus balloon angioplasty (BA). TLR, target lesion
evascularization; ISR, in-stent restenosis; DM, diabetes mel-
itus; DES, drug-eluting stent.
f TLR. In contrast, re-stenting with another DES plays a
rotective role against restenosis in patients with DES-ISR
ndergoing PCI.
In the era of BMS, morphologic pattern of ISR was the
ost important factor to predict recurrent restenosis after
CI for ISR. In particular, patients with diffuse ISR pattern
ere at high risk for recurrent restenosis after PCI. Pre-
ious studies demonstrated that 1-year TLR rate after PCI
or BMS-ISR was 14—19% for focal ISR pattern, and 35—46%
or diffuse ISR pattern [12,13]. On the other hand, the
atients with DES-ISR appear to have different peculiarities
hen compared to those with BMS-ISR. The ﬁrst, Colombo
t al. showed in an early report, was that the ISR after DES
mplantation was of a focal pattern and mostly inside the
tent [14]. Similar to that report, we also found the focal
SR pattern in 76.2% of patients. This morphologic change
f DES-ISR seems to reﬂect the suppressive effect of in-
tent neointimal hyperplasia by the DES. Unlike the focal
SR pattern of BMS, however, recurrence after treatment
f the focal ISR pattern of DES was relatively high in the
resent study (33.3%). Furthermore, subsequent TLR after
reatment of totally occluded ISR was at an unacceptably
igh rate (69.2%). These ﬁndings suggest that there may
e different biological mechanisms for recurrence of DES-
SR. Although the exact mechanisms are not known, the
ifferences in composition between DES and BMS might be
ble to account for mechanisms of DES-ISR. The DES is com-
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most frequently a polymer modifying drug-release kinetics.
It is well known in some cases with DES implantation that
non-absorbable polymer provokes chronic eosinophilic inﬁl-
tration of the stented vessel, suggesting allergic reactions
[15]. The polymer-induced inﬂammation may play a role in
ongoing and aggressive neointimal proliferation which is in a
total occlusive DES-ISR. Another possible explanation might
be the presence of drug resistance to either sirolimus or
paclitaxel. Theoretically, re-stenting with a different DES
(so-called “hetero” DES treatment) has the potential beneﬁt
of offering an alternative mechanism for preventing recur-
rent restenosis. However, a previous study has shown that
a strategy of using a different DES-type to that originally
implanted resulted in no differences between implanta-
tion of the same or a different DES in terms of preventing
binary restenosis and major adverse cardiac events [10].
Incidentally, stent fracture may represent a new potential
mechanism of restenosis after DES [16]. In our study, stent
fracture was observed in 6.7% of DES-ISR, but it was not
associated with an increased risk of recurrence after PCI in
patients with DES-ISR.
Diabetes mellitus has traditionally been considered a
major risk factor for the development of restenosis after
PCI with or without BMS implantation [17]. In the era
of DES, however, data from recent studies have not con-
sistently related diabetes mellitus with increased rate of
angiographic and clinical restenosis [18,19]. Interestingly,
we found that the presence of diabetes mellitus was asso-
ciated with recurrence after PCI for DES-ISR. There is a
paucity of pathophysiology data in diabetic patients with
DES-ISR, but Byrne et al. reported, with the results of 2-
year re-angiographic data in 1331 patients, that the time
course of restenosis in the DES era might be considered quite
different. They found that ongoing late lumen loss beyond
6—8 months post-index procedure is observed in diabetic
patients following DES implantation [20]. Several putative
mechanisms, including more aggressive intimal hyperplasia,
higher coagulability, a higher inﬂammatory response, and
endothelial dysfunction, have been postulated to account
for high recurrence after PCI in diabetic patients with DES-
ISR [17]. We therefore think that not only waiting for the
advance of DES technology, but also systemic approach to
improve hyperglycemia, insulin resistance, and endothelial
dysfunction are needed to reduce recurrence in patients
with DES-ISR.
As already shown in the present study, the rates of
angiographic restenosis and TLR were 37.9% and 33.3%,
respectively. In this regard, a relatively higher rate of
recurrence was observed than expected. Previous studies
have reported that binary restenosis rate was found to be
16.7—26.4% [10,21]. This discrepancy can be explained by
patient complexity of our study which had a high proportion
of patients with diabetes mellitus and hemodialysis. An addi-
tional factor may have been the use of balloon angioplasty
for treatment of DES-ISR. Indeed, the re-DES implantation
among our patients with DES-ISR was protective and binary
restenosis rate was 21.7%. Although a deﬁnitive conclusion
cannot be drawn in terms of the best strategy for treatment
of DES-ISR, at this moment it seems a reasonable therapeutic
approach to use re-stenting with a second DES. On the other
hand, concern has been raised that the stent sandwich strat-
egy, putting two or three stent-strut one over another, mayosis 395
ead to an occurrence of stent thrombosis [22]. Therefore,
e should be very careful in deciding on repeat revas-
ularization for patients with DES-ISR. The patients with
redictive factors, especially, may be needed to consider
or the indication of coronary artery bypass graft surgery.
ecently, a German group reported in patients with BMS-ISR,
hat paclitaxel-coated balloon was at least as efﬁcacious
nd as well tolerated as the paclitaxel-eluting stent. Late
umen loss at 6 months was 0.38mm in the paclitaxel-eluting
tent versus 0.17mm in the paclitaxel-coated balloon group,
= 0.03 [23]. Still, these data are from a small number of
atients, but this strategy may be necessary to overcome
ome of these limitations. The present analyses should be
nterpreted with caution because of the non-randomized
esign and relatively small population. However our data
re from multiple hospitals. Furthermore, we were also not
ble to make inferences about the relative efﬁcacy of het-
ro DES treatment because stent selection was not made
ecessarily on the basis of any protocol.
In conclusion, we have demonstrated that the rates
f angiographic restenosis and TLR are signiﬁcant in this
ohort of patients with DES-ISR. Angiographic pattern of
ES-ISR and the presence of diabetes mellitus are the most
mportant predictors of TLR, whereas re-stent implantation
ith a second DES is protective. These ﬁndings may facili-
ate improved outcomes after PCI in patients with DES-ISR.
rospective randomized trials to deﬁne the best treatment
n DES-ISR subsets are warranted.
eferences
[1] Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neoin-
timal tissue response at sites of coronary stenting in humans:
macroscopic, histological, and immunohistochemical analyses.
Circulation 1998;98:224—33.
[2] Eltchaninoff H, Koning R, Tron C, Gupta V, Cribier A. Balloon
angioplasty for the treatment of coronary in-stent resteno-
sis: immediate results and 6-month angiographic recurrent
restenosis rate. J Am Coll Cardiol 1998;32:980—4.
[3] vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner
HJ, Schiele F, Thomas M, Commeau P, Ramsdale DR, Garcia
E, Hamm CW, Hoffmann R, Reineke T, Klues HG. Rotational
atherectomy does not reduce recurrent in-stent restenosis:
results of the angioplasty versus rotational atherectomy for
treatment of diffuse in-stent restenosis trial (ARTIST). Circula-
tion 2002;105:583—8.
[4] Iijima R, Ikari Y, Anzai H, Nishida T, Tsunoda T, Nakamura M,
Hara K, Yamaguchi T. The impact of cutting balloon angioplasty
for the treatment of diffuse in-stent restenosis. J Invasive Car-
diol 2003;15:427—31.
[5] Stone GW, Ellis SG, O’Shaughnessy CD, Martin SL, Satler
L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma
JJ, Russell ME, TAXUS V ISR Investigators. Paclitaxel-eluting
stents vs vascular brachytherapy for in-stent restenosis within
bare-metal stents: the TAXUS V ISR randomized trial. JAMA
2006;295:1253—63.
[6] Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter
J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig
A, ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or
paclitaxel-eluting stent vs balloon angioplasty for prevention
of recurrences in patients with coronary in-stent restenosis: a
randomized controlled trial. JAMA 2005;293:165—71.
[7] Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR,















Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators.
Sirolimus-eluting stents versus standard stents in patients
with stenosis in a native coronary artery. N Engl J Med
2003;349:1315—23.
[8] Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig
A. Randomized trial of paclitaxel- and sirolimus-eluting stents
in small coronary vessels. Eur Heart J 2006;27:260—6.
[9] Qasim A, Cosgrave J, Latib A, Colombo A. Long-term follow-
up of drug-eluting stents when inserted for on- and off-label
indications. Am J Cardiol 2007;100:1619—24.
10] Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Babic R,
Airoldi F, Chieffo A, Sangiorgi GM, Montorfano M, Michev I, Car-
lino M, Colombo A. Repeated drug-eluting stent implantation
for drug-eluting stent restenosis: the same or a different stent.
Am Heart J 2007;153:354—9.
11] Kitahara H, Kobayashi Y, Takebayashi H, Fujimoto Y, Nakamura
Y, Kuroda N, Himi T, Miyazaki A, Haruta S, Komuro I. Re-
restenosis and target lesion revascularization after treatment
of sirolimus-eluting stent restenosis: retrospective analysis of
4 Japanese hospitals. Circ J 2009;73:867—71.
12] Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler
LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic pat-
terns of in-stent restenosis: classiﬁcation and implications for
long-term outcome. Circulation 1999;100:1872—8.
13] Nobuyoshi M, Yokoi H. How to manage in-stent restenosis.
Catheter Cardiovasc Interv 2000;49:30—1.
14] Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Mon-
torfano M, Liistro F, Carlino M, Airoldi F, Chieffo A, Di Mario
C. Preliminary observations regarding angiographic pattern of
restenosis after rapamycin-eluting stent implantation. Circu-
lation 2003;107:2178—80.15] Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta
T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized
hypersensitivity and late coronary thrombosis secondary to
a sirolimus-eluting stent: should we be cautious? Circulation
2004;109:701—5.Y. Takasawa et al.
16] Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama
T, Onuma Y, Higashikuni Y, Otsuki S, Yagishita A, Yachi S, Naka-
jima H, Hara K. Incidence and clinical impact of coronary stent
fracture after sirolimus-eluting stent implantation. Catheter
Cardiovasc Interv 2007;69:380—6.
17] Smith Jr SC, Faxon D, Cascio W, Schaff H, Gardner T, Jacobs A,
Nissen S, Stouffer R. Prevention conference VI: diabetes and
cardiovascular disease: writing group VI: revascularization in
diabetic patients. Circulation 2002;105:165—9.
18] Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache
J, Ibrahim M, Schömig A, Kastrati A. Impact of diabetes mellitus
on long-term outcomes in the drug-eluting stent era. Am Heart
J 2007;154:688—93.
19] Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache
J, Dirschinger J, Schömig A. Predictive factors of restenosis
after coronary implantation of sirolimus- or paclitaxel-eluting
stents. Circulation 2006;113:2293—300.
20] Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schömig A,
Kastrati A. Durability of antirestenotic efﬁcacy in drug-eluting
stents with and without permanent polymer. JACC Cardiovasc
Interv 2009;2:291—9.
21] Byrne R, Iijima R, Mehilli J, Pache J, Schulz S, Schömig A, Kas-
trati A. Treatment of paclitaxel-eluting stent restenosis with
sirolimus-eluting stent implantation: angiographic and clinical
outcomes. Rev Esp Cardiol 2008;61:1134—9.
22] Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E,
Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differen-
tial response of delayed healing and persistent inﬂammation
at sites of overlapping sirolimus- or paclitaxel-eluting stents.
Circulation 2005;112:270—8.
23] Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengsten-
berg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch
W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt
R, et al. Paclitaxel-coated balloon catheter versus paclitaxel-
coated stent for the treatment of coronary in-stent restenosis.
Circulation 2009;119:2986—94.
